Maria José García | Gastrointestinal Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Mrs. Maria José García | Gastrointestinal Pharmacology | Best Researcher Award

Hospital Universitario Marqués de Valdecilla | Spain

Mrs. María José García is a distinguished gastroenterologist renowned for her pioneering contributions to the understanding and treatment of inflammatory bowel diseases (IBD) and related gastrointestinal disorders. Currently serving as FEA Digestivo at the Hospital de Laredo, she has earned recognition as an accomplished clinician, educator, and researcher, with a strong commitment to advancing evidence-based gastroenterology. Her academic journey began with a degree in Medicine and Surgery from the University of Salamanca, followed by doctoral training in Biomedicine and Health Sciences at the University of Cantabria. This academic foundation, combined with her dedication to clinical excellence, has positioned her among the most respected figures in the field of digestive health.Her professional path includes prestigious international fellowships at Saint-Antoine Hospital in Paris and the Academic Medical Center in Amsterdam, where she deepened her expertise in the diagnosis and management of complex gastrointestinal conditions. These experiences allowed her to collaborate with leading European experts and integrate cutting-edge therapeutic innovations into clinical practice. Mrs. García’s research has been instrumental in shaping modern therapeutic approaches for IBD, particularly in evaluating biologic agents, third-line rescue therapies, and the withdrawal of antitumour necrosis factor treatments in patients achieving remission.Throughout her career, she has authored and co-authored numerous high-impact scientific articles published in prestigious journals such as Gut, Alimentary Pharmacology & Therapeutics, Therapeutic Advances in Gastroenterology, and Digestive and Liver Disease. Her most influential works have examined topics including inflammatory pouch disorders, safety and efficacy of advanced biologic therapies, and comparative analyses between novel treatment modalities for Crohn’s disease and ulcerative colitis. These studies have contributed valuable insights into optimizing patient care and personalizing treatment strategies across diverse clinical settings.Mrs. García’s scientific impact is underscored by an impressive record of 656 citations from 602 documents, 48 published papers, and an h-index of 14, reflecting both the quality and reach of her research. Her work continues to influence the global gastroenterology community, inspiring ongoing innovation and collaboration. Beyond research, she actively engages in knowledge dissemination through national and international conferences, promoting the integration of clinical practice with scientific discovery. Mrs. María José García stands as a model of excellence in gastroenterology—uniting clinical skill, academic rigor, and compassionate care to enhance the lives of patients worldwide.

Profile: Scopus

Featured Publications

Authors. (2025). Persistence, effectiveness, and safety of upadacitinib in Crohn’s disease and ulcerative colitis in real life: Results from a Spanish nationwide study (Ureal Study). American Journal of Gastroenterology.

Authors. (2025). Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: A randomised placebo-controlled clinical trial of GETECCU. Gut.

Authors. (2025). Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU. Digestive and Liver Disease.

Authors. (2025). Exploration of fecal microbiota in newly diagnosed patients with inflammatory bowel disease using shotgun metagenomics. Frontiers in Cellular and Infection Microbiology.

Feng Jiang | Cardiovascular Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Feng Jiang | Cardiovascular Pharmacology | Best Researcher Award

Stanford University | United States

Dr. Feng Jiang is a highly accomplished postdoctoral researcher at Stanford University, specializing in uncovering the mechanisms and risk factors of human autoimmune diseases. His research focuses on performing experiments and bioinformatic analyses on genetic and RNA-seq data to identify key disease mechanisms and develop therapeutics targeting these pathways. He has also established predictive models based on risk factors to enable early diagnosis of autoimmune conditions. Prior to his postdoctoral work, Dr. Jiang completed his Ph.D. at the University of Rochester, where he conducted extensive research targeting profibrotic genes to combat cardiac fibrosis. His work involved identifying common regulators controlling the expression of profibrotic genes, inhibiting their activity in animal models, and exploring the regulation of mRNA translation in cancer and heart disease. Additionally, he investigated the role of microRNAs in disease, identifying key microRNAs involved in disease progression and their potential as biomarkers for diagnosis and monitoring.Dr. Jiang also gained international research experience as a research fellow at Yat-sen University, where he executed sequencing library construction and established analysis pipelines for human and mouse samples. During his undergraduate studies at Wuhan University, he investigated the role of the gene GLIS2 in cancer progression using CRISPR/Cas9 gene editing techniques.He has contributed significantly to the scientific literature with numerous impactful publications, including works such as RNA Binding Protein PRRC2B Mediates Translation of Specific mRNAs and Regulates Cell Cycle Progression, Glutamyl-Prolyl-tRNA Synthetase Regulates Proline-Rich Pro-Fibrotic Protein Synthesis During Cardiac Fibrosis, Mammalian RNA Switches: Molecular Rheostats in Gene Regulation, Disease, and Medicine, MicroRNA574 Regulates FAM210A Expression and Influences Pathological Cardiac Remodeling, Correlation Between Severity of Spinal Stenosis and Multifidus Atrophy in Degenerative Lumbar Spinal Stenosis, Usage of Procalcitonin and sCD14-ST as Diagnostic Markers for Postoperative Spinal Infection, Correlations Between Serum P2X7, Vitamin A, 25-Hydroxy Vitamin D, and Mycoplasma Pneumoniae Pneumonia, Disruption of Tdrd5 Decouples the Stepwise Processing of Long Precursor Transcripts During Pachytene PIWI-Interacting RNA Biogenesis, and Cardiomyocyte-Specific Loss of Glutamyl-Prolyl-tRNA Synthetase Leads to Disturbed Protein Homeostasis and Dilated Cardiomyopathy.

Profile: Google Scholar

Featured Publications

Jiang, F., Hedaya, O. M., Khor, E. S., Wu, J., Auguste, M., & Yao, P. (n.d.). RNA binding protein PRRC2B mediates translation of specific mRNAs and regulates cell cycle progression. Nucleic Acids Research.

Wu, J., Subbaiah, K. C. V., Xie, L. H., Jiang, F., Khor, E. S., Mickelsen, D., Myers, J. R., Tang, W. H. W., & Yao, P. (n.d.). Glutamyl-prolyl-tRNA synthetase regulates proline-rich pro-fibrotic protein synthesis during cardiac fibrosis. Circulation Research.

Wu, J., Subbaiah, K. C. V., Jiang, F., Hedaya, O., Mohan, A., Yang, T., Welle, K., Ghaemmaghami, S., Tang, W. H. W., Small, E., Yan, C., & Yao, P. (n.d.). MicroRNA-574 regulates FAM210A expression and influences pathological cardiac remodeling. EMBO Molecular Medicine.

Subbaiah, K. C. V., Hedaya, O., Wu, J., Jiang, F., & Yao, P. (n.d.). Mammalian RNA switches: Molecular rheostats in gene regulation, disease, and medicine. Computational and Structural Biotechnology Journal.

Hedaya, O. M., Venkata Subbaiah, K. C., Jiang, F., Xie, L. H., Wu, J., Khor, E. S., Zhu, M., Mathews, D. H., Proschel, C., & Yao, P. (n.d.). Secondary structures that regulate mRNA translation provide insights for ASO-mediated modulation of cardiac hypertrophy. Nature Communications.

Xia, G., Li, X., Shang, Y., Fu, B., Jiang, F., Liu, H., & Qiao, Y. (n.d.). Correlation between severity of spinal stenosis and multifidus atrophy in degenerative lumbar spinal stenosis. BMC Musculoskeletal Disorders.

Zhu, X., Li, K., Zheng, J., Xia, G., Jiang, F., Liu, H., & Shi, J. (n.d.). Usage of procalcitonin and sCD14-ST as diagnostic markers for postoperative spinal infection. Journal of Orthopaedics and Traumatology.

Li, W., Li, Y., Jiang, F., & Liu, H. (n.d.). Correlation between serum levels of microRNA-21 and inflammatory factors in patients with chronic heart failure. Medicine.

Muneeb Ullah | Nanomedicine | Innovator in Pharmaceutical Research Award

Published on by Top Pharmaceutical

Mr. Muneeb Ullah | Nanomedicine | Innovator in Pharmaceutical Research Award

Pusan National University | South Korea

Mr. Muneeb Ullah is a dedicated pharmaceutical scientist and research assistant at the Department of Pharmacy, Pusan National University, Busan, South Korea. His academic journey reflects a strong foundation in pharmaceutics, nanomedicine, and advanced drug delivery systems. With a Doctoral pursuit in Pharmacy at Pusan National University, his research focuses on nanoparticle preparation and novel therapeutic approaches for biofilm-associated wound healing, colon cancer, inflammatory bowel disease, and diabetic wound healing.Mr. Ullah’s earlier academic achievements include an MPhil in Pharmaceutical Sciences with a specialization in Pharmaceutical Nanotechnology from Kohat University of Science and Technology (KUST), Pakistan, where he conducted advanced research on the development of polymeric nanoparticles using the water-in-oil emulsion solvent evaporation method. His Pharm-D degree from KUST provided a robust grounding in pharmaceutics, pharmacology, biochemistry, and pharmaceutical chemistry, further shaping his expertise in nanotechnology-based therapeutics.Throughout his academic and professional career, he has demonstrated exceptional dedication and excellence. He has received several honors, including the Higher Education Commission Indigenous Scholarship, the Prime Minister Laptop Scheme’s Best Talent Award, the Best Teacher Award, and multiple Best Researcher Awards. His multidisciplinary experience includes teaching, research supervision, and laboratory expertise encompassing nanoparticle synthesis, animal handling for wound healing studies, HPLC, ELISA, UV spectrophotometry, zeta sizer analysis, and confocal microscopy.Mr. Ullah’s research contributions have significantly advanced the field of pharmaceutical nanotechnology. His publications span reputable journals and book chapters with publishers such as CRC Press and Academic Press. His works explore diverse topics, including genetic engineering of fungi, sugar nanocluster adhesives for diabetic wound healing, advancements in 3D and 4D bioprinting for sustained drug delivery, biomedical applications of carbon dots, tumor microenvironment biology, gastrointestinal inflammation, and nanoparticle-based oral cancer therapies. His studies on alginate-based tumor-selective nanoparticle delivery and cancer nanomedicine have been widely cited for their innovation and translational potential.To date, Mr. Ullah has contributed to 37 scholarly documents, amassing a total of 470 citations, with an h-index of 11, reflecting the influence and recognition of his research in the global scientific community. With this growing research impact, he continues to contribute to cutting-edge pharmaceutical research with a vision to design smarter, safer, and more efficient nanotherapeutics that bridge the gap between laboratory innovation and clinical application.

Profile: Scopus

Featured Publications

Author(s). (2025). Leukocyte esterase-activated nanoconjugates enables precise local therapy of ulcerative colitis via inflamed tissue-selective drug delivery. ACS Applied Materials and Interfaces.

Author(s). (2025). Sugar nanocluster adhesive boosts wound healing in diabetic mice. Carbohydrate Polymer Technologies and Applications.

Author(s). (2025). Genetic engineering of fungi.

Rabab Abdel Moneim | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. Rabab Abdel Moneim | Personalized Medicine | Best Researcher Award

Cairo University | Egypt

Prof. Dr. Rabab Abdel Moneim is a distinguished authority in Clinical Oncology at the Kasr El Aini Faculty of Medicine, Cairo University, Cairo, Egypt. With an extensive career dedicated to cancer research, radiotherapy, and clinical practice, she has made a profound impact on oncology education, treatment innovation, and patient care across the Middle East. Her academic foundation was established at the renowned Kasr El Aini Faculty of Medicine, where she completed her M.B.B.Ch. degree with honors, followed by a master’s degree in Medical Oncology and Radiotherapy, earning the highest distinction across all Cairo universities. She later attained her Doctorate in Oncology, cementing her status as a leading scholar and clinician in the field.Prof. Abdel Moneim has accumulated rich professional experience through her long-standing affiliation with the Kasr El Aini Faculty of Medicine, where she has served in multiple academic and clinical capacities, advancing from house officer and resident to assistant lecturer, assistant professor, and eventually full professor. Her clinical expertise is reflected in her consultancy roles at the New Kasr El-Eini Teaching Hospital and the IMC Hospital Radiotherapy Center. Her early professional journey includes collaboration with Prof. Dr. Hamdy Abd El Azim at the Cairo Cure Center, a partnership that shaped her clinical vision and deepened her specialization in oncology and radiotherapy.Her professional experience extends beyond Egypt, having served as a consultant at King Fahd Hospital in Madina, Saudi Arabia, and maintaining an active registration with the Saudi Commission for Health Specialties in Oncology Medicine. Prof. Abdel Moneim’s commitment to global oncology advancement is further demonstrated through her participation in numerous international conferences and workshops, including ESMO, ESTRO, ASCO, and other major oncology congresses. Her contributions to evidence-based cancer therapy, radiotherapy techniques, and the facilitation of clinical trials across the MENA region have significantly influenced modern oncology practices.An active member of multiple professional societies such as ESTRO, ESMO, the Sarcoma Group, and the Neuro-Oncology Group at Cairo University, Prof. Abdel Moneim continues to contribute to academic excellence and clinical innovation. Her expertise in 3D conformal radiation therapy, stereotactic techniques, IMRT, and RapidArc has set a high standard in radiotherapy advancements. As a dedicated educator, she remains involved in postgraduate teaching and training programs, nurturing the next generation of oncologists.

Profile: Google Scholar

Featured Publications

Abdel Moneim, A. A. R., & El Deeb, M. (2017). Gingival pigmentation: Cause, treatment, and histological preview. Future Dental Journal.

Rady, D., Mubarak, R., & Abdel Moneim, R. A. (2018). Healing capacity of bone marrow mesenchymal stem cells versus platelet-rich fibrin in tibial bone defects of albino rats: An in vivo study. F1000Research.

Abdel Moneim, R. A., El Deeb, M., & Adel, F. (2018). Evaluation of the therapeutic potential of Tamarind seeds (aqueous extract) versus antidiabetic drugs on the histological structure of lingual papillae in diabetic rats. Egyptian Dental Journal, 64(3), Oral Medicine, X-Ray, Oral Biology Section.

Hakam, H. M., Abdel Moneim, R. A., & El Deeb, M. F. (2020). Osteoinductive potential and bone healing capacity of nanocrystalline hydroxyapatite (nHA) versus Biodentine of surgically created defects in rabbits’ alveolar process (an experimental study). Egyptian Journal of Histology.

Abdel Moneim, R. A., Mostafa, A., & Abbass, M. M. S. (2020). In treating glucocorticoid-induced osteoporosis in temporomandibular joint of albino rats; which are more effective: Microvesicles or mesenchymal stem cells? Egyptian Journal of Histology.

El Deeb, M., & Abdel Moneim, R. A. (2018). Remineralization potential of lactose-free and plant-based milk on enamel surface of human teeth subjected to energy drinks. Egyptian Dental Journal, 64(4), Oral Medicine, X-Ray, Oral Biology Section.

Ragaei, A., & Abdel Moneim, R. A. A. (2017). Gingival overgrowth: Drug-induced versus hereditary and idiopathic. Cosmetology & Oro Facial Surgery.

Biaoru Li | Personalized Medicine | Oncolog Oncopharm Research Achievement

Published on by Top Pharmaceutical

Dr. Biaoru Li | Personalized Medicine | Oncolog Oncopharm Research Achievement

Medical College of GA | United States

Dr. Biaoru Li is an accomplished leader in the fields of precision medicine, genomics, and personalized immunotherapy, with extensive experience spanning clinical hematology, oncology, and advanced molecular research. His expertise bridges the continuum from bio-specimen preparation to clinical application, integrating cutting-edge biobanking, primary cell sorting, single-cell identification, and functional genomics. Dr. Li’s research delves deeply into the cellular and molecular mechanisms that drive disease, with a particular focus on CD34 cells, erythroid cells, T-cells, and primary tumor cells. His work emphasizes the transformation of primary bio-specimens into powerful genomic insights through advanced technologies such as next-generation sequencing (NGS) and microarray analysis.A pioneer in precision medicine, Dr. Li has made substantial contributions to the development of personalized immunotherapy strategies and the integration of artificial intelligence into biomedical research. His ongoing projects include the design of AI-driven models that enhance diagnostic accuracy and therapeutic prediction for cancer and immune-related disorders. Dr. Li’s innovative research on single-cell RNA sequencing has opened new pathways for individualized treatment, offering a molecular-level understanding of disease heterogeneity.As an academic and clinical researcher, Dr. Li has established collaborations with hospitals and research institutions across the United States and Asia, promoting global scientific exchange and clinical translation. His scholarly impact is reflected in his numerous publications indexed in prestigious scientific databases such as SCI and Scopus, as well as his extensive citation record on Google Scholar and ORCID. Dr. Li’s editorial influence extends across 17 international editorial boards, where he contributes to advancing scientific standards in molecular medicine and clinical genomics.In addition to his academic achievements, Dr. Li has authored influential books, including Personalized Immunotherapy for Tumor Disease and Beyond and Personalized Therapy for PAH and Beyond, both of which underscore his leadership in developing targeted therapeutic frameworks. His membership in renowned professional societies, including the American Society of Hematology and the Royal Society of Medicine, underscores his commitment to advancing medical science and mentoring future researchers.

Profile: Orcid

Featured Publications

Li, S., & Li, B. (2025). Precision medicine related to landscape and architecture of tumor specimen. Japan Journal of Research.

Song, P., & Li, B. (2025). New generation of clinical epigenetics analysis and diagnosis for precision medicine. Diagnostics.

Palani, C. D., Smith, A., Cao, X., Li, B., Pace, B. S., & Starlard‐Davenport, A. (2025). Cholesterol‐conjugated miR‐29b induces fetal haemoglobin expression via γ‐globin promoter demethylation in the Townes mouse model for sickle cell anaemia. British Journal of Haematology.

Yang, Y., Chen, S., Li, W., Duan, J. C., Yuan, Y., Xie, V. S., & Li, B. (2024). STAT3 down-regulation for IL-2 inducing TIL-A clinical clue for spatial quantitative pathway analysis. AIMS Allergy and Immunology.

Li, B. (2024). Surgery and specimen biobanks—Tumor tissues and precision medicine. Journal of Surgery.

Li, B. (2024). Prediction, prevention, prognostic and personalized therapy of ovarian cancer—Biomarkers and precision medicine. Biomedical Journal of Scientific and Technical Research.

Yang, Y., Li, W., Chen, S., Yuan, Y., & Li, B. (2023). Spatial-timely quantitative network analysis for TGF-β pathway of tumor infiltrating lymphocytes. Journal of Cancer Science and Clinical Therapeutics.

Zhu, X., & Li, B. (Eds.). (2023). Epigenetics in cancer: Mechanisms and drug development – Volume II. Frontiers Research Topics.

Li, B. (2023). Personalized immunotherapy of patients: Defining by single-cell RNA-seq with artificial intelligence. Medical Research Archives.

Yunmeng Liu | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Assist. Prof. Dr. Yunmeng Liu | Immunotherapy | Best Researcher Award

University of Arkansas for Medical Sciences | United States

Dr. Yunmeng Liu is a highly accomplished biomedical scientist and pharmacologist specializing in the interplay between immunity, metabolism, and cardiovascular health. With a robust academic foundation in molecular biology and integrated biomedical science, Dr. Liu has devoted her career to unraveling the cellular and molecular mechanisms underlying hypertension, diabetes, and related cardiovascular complications. She currently serves as a Research Assistant Professor in the Department of Pharmacology and Toxicology at UAMS, where she leads innovative projects exploring the immune system’s role in metabolic and cardiovascular diseases. Her research integrates advanced techniques in pharmacology, immunology, and molecular biology to develop new therapeutic strategies for complex chronic conditions.Dr. Liu’s extensive research contributions are reflected in numerous high-impact publications. She has investigated P2X7-mediated activation of CD8+ T cells and their role in promoting salt-sensitive hypertension, providing critical insights into the immune modulation of blood pressure. Her work on interferon gamma pathways enhancing CD8 T cell interactions in hypertension and the stimulation of the Na-Cl co-transporter NCC by CD8+ T cells in distal convoluted tubules highlights the molecular crosstalk between immune cells and renal physiology. She has also explored immune dysregulation connecting type 2 diabetes and cardiovascular complications, emphasizing how chronic metabolic imbalances influence immune cell behavior and disease progression.Other notable contributions include the role of KATP channel openers in inhibiting lymphatic contractions and lymph flow as a mechanism of peripheral edema, and Eplerenone-mediated attenuation of fibrosis in the contralateral kidney by preventing macrophage-to-myofibroblast transition, which underscore her translational approach bridging basic research and clinical relevance. Additionally, she has advanced knowledge on resident-memory T cell establishment anchoring hypertension in the kidney and the nutrition impact on diabetes and cardiovascular health, reflecting her commitment to holistic understanding of disease mechanisms.Beyond her research, Dr. Liu is deeply engaged in education and mentorship, instructing graduate students in courses such as cell biology, pathologic basis of disease, and pharmacology and therapeutics, while supervising numerous PhD and undergraduate students in cutting-edge biomedical research projects. Her scholarly excellence is recognized through awards, grant funding, and memberships in professional societies including the American Heart Association, American Diabetes Association, and American Association of Immunologists, solidifying her status as a leading expert in immunopharmacology and cardiovascular-metabolic research.

Profile: Orcid

Featured Publications

Deck, K., Mora, C., Deng, S., Rogers, P., Rafferty, T., Palade, P. T., Mu, S., & Liu, Y. (2025). Immune dysregulation connecting type 2 diabetes and cardiovascular complications. Life, 15(8), 1241.

Liu, Y. (2024, May 29). Immune disorders connecting type 2 diabetes and cardiovascular complications [Preprint].

Benson, L., Deck, K., Mora, C., Guo, Y., Rafferty, T. M., Li, L.-X., Huang, L., Qin, Z., Andrews, J. T., & Liu, Y. (2024, January 9). P2X7-mediated antigen-independent activation of CD8 T cells promotes salt-sensitive hypertension. Hypertension (Dallas, Tex.: 1979).

Benson, L. N., Guo, Y., Deck, K., Mora, C., Liu, Y., & Mu, S. (2023, March 9). The link between immunity and hypertension in the kidney and heart. Frontiers in Cardiovascular Medicine, 10, 1129384.

Benson, L. N., Liu, Y., Deck, K., Mora, C., & Mu, S. (2022, October 26). IFNγ contributes to the immune mechanisms of hypertension. Kidney360, 3(10), 1234–1246.

Fatemeh Haddadi | Pharmaceutical Biotechnology | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Fatemeh Haddadi | Pharmaceutical Biotechnology | Best Researcher Award

University of Zabol | Iran

Dr. Fatemeh Haddadi is a distinguished Iranian scientist and academic, recognized for her pioneering contributions to plant biotechnology, nanobiotechnology, genetic engineering, and molecular genetics. She earned her Bachelor of Science in Plant Biology from the University of Zabol, followed by both her Master’s and Ph.D. degrees in Plant Biotechnology from Universiti Putra Malaysia. Over the years, she has established herself as an influential figure in academia and research, combining advanced molecular methods with applied biotechnology to address agricultural and biomedical challenges.Dr. Haddadi began her academic career as a Special Graduate Research Assistant at Universiti Putra Malaysia, where she actively contributed to groundbreaking research in plant tissue culture and molecular biology. Upon returning to Iran, she joined the University of Zabol as an Assistant Professor, where she continues to teach and supervise both undergraduate and postgraduate students in subjects such as genetics, molecular genetics, genetic engineering, molecular biology, animal biotechnology, and bioinformatics. Her mentorship has guided dozens of graduate students, helping to shape the next generation of biotechnologists.In addition to her academic roles, Dr. Haddadi serves as the Head of Zand Biotechnology Company, a knowledge-based enterprise specializing in biotechnology and genetic engineering innovations. Under her leadership, the company has developed several advanced biotechnological products, including DNA isolation kits from gel, blood, and plants, which have achieved Technology Readiness Level (TRL) 7 recognition by Iran’s national technology assessment authority. Her dedication to translational research bridges the gap between laboratory discovery and industrial application, emphasizing practical solutions for real-world scientific needs.Dr. Haddadi’s innovative spirit has been recognized with several prestigious accolades, including the Khwarizmi Award, multiple medals from the PRPI Invention, Research and Innovation Exhibition, and national awards for knowledge-based products and scientific entrepreneurship. Her scientific influence extends through an impressive portfolio of peer-reviewed publications, including research on micropropagation of strawberry, Agrobacterium-mediated transformation, and the development of gold nanoparticle-based biosensors for molecular detection and gene transformation.

Profile: Google Scholar

Featured Publications

Haddadi, F., Abd Aziz, M., Saleh, G., Abd Rashid, A., & Kamaladini, H. (n.d.). Micropropagation of strawberry cv. Camarosa: Prolific shoot regeneration from in vitro shoot tips using thidiazuron with N6-benzylamino-purine. HortScience, 45(3), 453–456.

Khodavirdipour, A., Haddadi, F., & Keshavarzi, S. (n.d.). Chromium supplementation; negotiation with diabetes mellitus, hyperlipidemia and depression. Journal of Diabetes & Metabolic Disorders, 19(1), 585–595.

Ahmadi, S., Kamaladini, H., Haddadi, F., & Sharifmoghadam, M. R. (n.d.). Thiol-capped gold nanoparticle biosensors for rapid and sensitive visual colorimetric detection of Klebsiella pneumoniae. Journal of Fluorescence, 28(4), 987–998.

Haddadi, F., Abd Aziz, M., Abdullah, S. N. A., Tan, S. G., & Kamaladini, H. (n.d.). An efficient Agrobacterium-mediated transformation of strawberry cv. Camarosa by a dual plasmid system. Molecules, 20(3), 3647–3666.

Haddadi, F., Abd Aziz, M., Kamaladini, H., & Ravanfar, S. A. (n.d.). Thidiazuron- and zeatin-induced high-frequency shoot regeneration from leaf and shoot-tip explants of strawberry. HortTechnology, 23(3), 276–281.

Ravanfar, S. A., Abd Aziz, M., Abd Kadir, M., Abd Rashid, A., & Haddadi, F. (n.d.). In vitro adventitious shoot regeneration and acclimatisation of Brassica oleracea subsp. italica cv. Green Marvel. African Journal of Biotechnology, 10(29), 5614–5619.

Osmani Bojd, M., Kamaladini, H., Haddadi, F., & Vaseghi, A. (n.d.). Thiolated AuNP probes and multiplex PCR for molecular detection of Staphylococcus epidermidis. Molecular and Cellular Probes, 34, 30–36.

Luca Roncati | Pharmacovigilance | Best Academic Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. Luca Roncati | Pharmacovigilance | Best Academic Researcher Award

Link Campus University | Italy

Prof. Dr. Luca Roncati is a distinguished Italian pathologist, physician-scientist, and academic leader whose extensive contributions have significantly advanced modern medical science. With a strong focus on senology, gynecologic oncology, gynecopathology, and hematopathology, he stands as a prominent figure in the global medical community. Dr. Roncati has an impressive record of 228 scientific publications, collectively cited in over 1,073 documents with more than 1,738 total citations, reflecting the profound influence and credibility of his research across various medical disciplines.Renowned for his groundbreaking discoveries, Dr. Roncati is the eponym of the Roncati–Manenti Triad, a key diagnostic concept in gynecologic oncology, and the describer of T rex lymphoma, a rare hematological condition that broadened the understanding of lymphoid malignancies. As a pioneering researcher in COVID-19, his investigations provided critical insights into viral pathogenesis and immune mechanisms, shaping the scientific response during the global pandemic. Furthermore, his innovative work in nanopathology has paved the way for the integration of nanotechnology into modern diagnostic pathology, offering revolutionary approaches to disease detection at the molecular level.Beyond research, Dr. Roncati is a full-time Professor of Pathology at Link Campus University in Rome, where he mentors future medical professionals and drives forward-thinking educational programs in biomedical sciences. Simultaneously, he leads as the Head of the Women’s Health Department at the European Institute of Dermatology in Milan, where his expertise in women’s health, oncology, and diagnostic pathology enhances patient care and clinical outcomes.An award-winning author, academic editor, and inventor of anti-cancer patents, Dr. Roncati’s contributions exemplify the synergy between innovation, clinical excellence, and scientific discovery. His scholarly achievements, coupled with his dedication to advancing medical knowledge, have established him as one of the most influential figures in contemporary pathology and translational medicine. Through his research, publications, and leadership, Prof. Dr. Luca Roncati continues to inspire a new generation of scientists and clinicians in their pursuit of excellence and innovation in healthcare.

Profile: Scopus

Featured Publications

Roncati, L., et al. (2025). Erratum: Long COVID clinical evaluation, research and impact on society: a global expert consensus. Annals of Clinical Microbiology and Antimicrobials.

Roncati, L., et al. (2025). Long COVID clinical evaluation, research and impact on society: a global expert consensus. Annals of Clinical Microbiology and Antimicrobials.

Roncati, L., et al. (2025). pDNA impurities in mRNA vaccines. Editorial, Open Access.

Roncati, L., et al. (2025). Thoracic aortic pseudoaneurysm: Inside its pathophysiology. Vascular.

Roncati, L., et al. (2025). Adjuvant metronomic chemotherapy after surgery in pT1–T2 N0 M0 HER2-positive and ER/PR-positive breast cancer plus targeted therapy, anti-hormonal therapy, and radiotherapy, with or without immunotherapy: A new operational proposal. Editorial, Open Access.

Roncati, L., et al. (2025). Ozone–oxygen therapy to prevent HPV-related cancers of the lower gynecological tract in infected patients: The rationale for further developments. Cancers. [Open Access]

Roncati, L., et al. (2025). COVID-19 and upper limb compression neuropathies: A review. Review Article, Open Access.

Karanvir Singh | Medicinal Chemistry | Best Researcher Award

Published on by Top Pharmaceutical

Mr. Karanvir Singh | Medicinal Chemistry | India

Guru Nanak Dev University | India

Mr. Karanvir Singh is a dynamic and highly skilled researcher in the field of pharmaceutical chemistry, currently pursuing his Doctorate of Philosophy at the Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, India. His ongoing doctoral research, under the supervision of Prof. Dr. Preet Mohinder Singh Bedi, focuses on the design and synthesis of 1,2,4-triazine hybrids with Nipecotic acid for anticonvulsant activity, emphasizing computational modeling, synthesis, and biological evaluation of novel anticonvulsant agents. He holds a Master’s degree in Pharmacy (Pharmaceutical Chemistry) from ISF College of Pharmacy, Moga, Punjab, where he completed a thesis on the design and synthesis of 1,2,4-triazine derivatives for anticonvulsant activity under the guidance of Dr. Vikramdeep Monga and Dr. Bhupinder Kumar. His strong academic foundation was built upon a Bachelor of Pharmacy from the Laureate Institute of Pharmacy, Himachal Pradesh.With a blend of academic excellence and industrial exposure, Mr. Singh has worked as an Assistant QA Chemist at United Biotech Pvt. Ltd., where he gained extensive experience in pharmaceutical quality assurance. His scientific expertise spans molecular docking, fragment-based drug design, pharmacophore modeling, molecular dynamics simulations, organic synthesis, compound purification, and structural elucidation using analytical tools such as NMR, FT-IR, HPLC, and Mass spectrometry.Mr. Singh has made significant contributions to the scientific community, authoring multiple research and review articles in reputed journals. His notable publications include Design, Synthesis, and Biological Evaluation of Triazole-Linked Lignan–Monoterpenoid-Based Hybrid Molecules as Xanthine Oxidase Inhibitors with Potent In Vivo Efficacy; Design, Synthesis, and Multi-Target Biological Evaluation of 1,2,3-Triazole Linked Indole–Thiazolidinedione Hybrids as Potent α-Glucosidase, α-Amylase, and DPP-4 Inhibitors with Antioxidant Potential; Design, Synthesis, Antibacterial Evaluation, and Molecular Modelling Studies of 1,2,3-Triazole-Linked Coumarin–Vanillin Hybrids as Potential DNA Gyrase and Topoisomerase IV Inhibitors; and Development of Coumarin-Inspired Bifunctional Hybrids as a New Class of Anti-Alzheimer’s Agents with Potent In Vivo Efficacy. His review works, such as Exploring Norfloxacin Analogs in Combating Antimicrobial Resistance: Design, Mechanistic Insights, and Structure–Activity Relationship and Incredible Indolinedione Derivatives Nucleus in the Development of Anti-Diabetic Drugs: Exploring the Mechanistic Studies, Design, and Structure–Activity Relationship, further demonstrate his broad research vision and scientific depth.

Profile: Google Scholar

Featured Publications

Singh, K., Pal, R., Khan, S. A., Kumar, B., & Akhtar, M. J. Insights into the structure–activity relationship of nitrogen-containing heterocyclics for the development of antidepressant compounds: An updated review. Journal of Molecular Structure.

Singh, A., Malhotra, D., Singh, K., Chadha, R., & Bedi, P. M. S. Thiazole derivatives in medicinal chemistry: Recent advancements in synthetic strategies, structure–activity relationship, and pharmacological outcomes. Journal of Molecular Structure.

Singh, A., Singh, K., Sharma, A., Kaur, K., Kaur, K., Chadha, R., & Bedi, P. M. S. Recent developments in synthetic α-glucosidase inhibitors: A comprehensive review with structural and molecular insight. Journal of Molecular Structure.

Pal, R., Singh, K., Khan, S. A., Chawla, P., Kumar, B., & Akhtar, M. J. Reactive metabolites of the anticonvulsant drugs and approaches to minimize the adverse drug reaction. European Journal of Medicinal Chemistry.

Singh, A., Singh, K., Sharma, A., Kaur, K., Chadha, R., & Bedi, P. M. S. Recent advances in antifungal drug development targeting lanosterol 14α-demethylase (CYP51): A comprehensive review with structural and molecular insights. Chemical Biology & Drug Design.

Samaneh Moradi | Antibiotic Resistance | Best Faculty Award

Published on by Top Pharmaceutical

Dr. Samaneh Moradi | Antibiotic Resistance | Best Faculty Award

Golestan University | Iran

Dr. Samaneh Moradi is a distinguished researcher and educator specializing in medical microbiology, with a strong academic foundation from the Department of Microbiology, Faculty of Science, Golestan University, Gorgan, Iran. She holds a Ph.D. in Medical Microbiology, where her doctoral research was centered on a systematic review of the prevalence of antibacterial resistance in Enterococcus faecalis outside clinical settings, with a particular emphasis on animals, food, and environmental sources. Her work reflects a deep commitment to understanding the complex pathways of bacterial resistance and its implications for both human and environmental health.With over 12 years of hands-on laboratory and research experience, Dr. Moradi has developed extensive expertise in a wide range of microbiological and molecular biology techniques. Her practical experience includes conducting ELISA assays, utilizing advanced diagnostic platforms such as Cobas e411, Immulite 200, and Sysmex instruments, as well as performing cell counting and viability assessments through both automated and manual methods. She has worked proficiently with cell culture models such as Caco-2 cells, enabling her to explore host-pathogen interactions and antimicrobial responses at the cellular level. Her proficiency further extends to real-time PCR, Western blotting, and microbial diagnostics and identification, underscoring her technical versatility and analytical precision.Dr. Moradi’s research contributions include several peer-reviewed publications, with five articles published and three additional manuscripts recently submitted for consideration. Her work integrates advanced immunoassays, molecular biology, and clinical microbiology diagnostics, reflecting her multidisciplinary approach to microbial research. She is also well-versed in statistical data analysis and interpretation, frequently employing SPSS software for data-driven insights that enhance the validity and reliability of her scientific outcomes.Her scientific journey is characterized by a balance of academic excellence and practical expertise, enabling her to contribute meaningfully to contemporary challenges in infectious diseases, antibiotic resistance, and diagnostic innovation. Based at the Department of Microbiology, Golestan University, Dr. Samaneh Moradi continues to advance microbiological research through her dedication, precision, and pursuit of knowledge aimed at improving public health outcomes and microbial understanding across clinical and environmental domains.

Profile: Google Scholar

Featured Publications

Guan, L., Beig, M., Wang, L., Navidifar, T., Moradi, S., Motallebi Tabaei, F., & others. (n.d.). Global status of antimicrobial resistance in clinical Enterococcus faecalis isolates: Systematic review and meta-analysis. Annals of Clinical Microbiology and Antimicrobials.

Huang, C., Moradi, S., Sholeh, M., Tabaei, F. M., Lai, T., Tan, B., Meng, J., & Azizian, K. (n.d.). Global trends in antimicrobial resistance of Enterococcus faecium: A systematic review and meta-analysis of clinical isolates. Frontiers in Pharmacology.

Farsimadan, M., Heravi, F. S., Emamvirdizadeh, A., Moradi, S., Iranpour, H., & others. (n.d.). Evaluation of Helicobacter pylori genotypes in obese patients with gastric ulcer, duodenal ulcer, and gastric cancer: An observational study. Digestive Diseases.

Yang, Y., Yeganeh, R., Moghadam, M. A., Teymouri, Z., Tabaei, F. M., Moradi, S., & others. (n.d.). Global antibiotic resistance trends in Enterococcus faecalis from animals, food, and environmental sources: A meta-analysis. Preventive Veterinary Medicine.